A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Active:	No
Cancer Type:	Multiple Myeloma	NCT ID:	NCT03287908
Trial Phases:	Phase I	Protocol IDs:	20170122 (primary) NCI-2017-02084 2017-001997-41
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Amgen, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT03287908

Summary

The primary purpose of the phase 1 part of the study is to evaluate safety and tolerability
of AMG 701 monotherapy to identify the RP2D for AMG 701 monotherapy followed by a
dose-confirmation part to gather further safety data for AMG 701 monotherapy at the RP2D in
adult subjects with relapsed/refractory multiple myeloma (RRMM). In addition, this study will
include a sequential dose exploration part to identify the RP2D of AMG 701 in combination
with pomalidomide, with and without dexamethasone (AMG 701-P+/-d). Phase 2 will consist of
the dose-expansion part to gain further efficacy and safety experience with AMG 701
monotherapy in adult subjects with RRMM.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.